Clinical Trials Directory

Trials / Completed

CompletedNCT03399214

Phase Ib, Administration the IOP Injection for MRI Contrast Agent in Healthy Subjects

A Phase Ib Study to Evaluate Safety and Efficacy Profiles of IOP Injection for Magnetic Resonance Imaging (MRI) Contrast Agent in Healthy Subjects.

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
12 (actual)
Sponsor
MegaPro Biomedical Co. Ltd. · Industry
Sex
Male
Age
20 Years – 40 Years
Healthy volunteers
Accepted

Summary

The objective of the study is to assess the dose dependent changes in MRI signal intensity (SI) in liver after IOP Injection intravenous administration in healthy volunteers.

Detailed description

Find the max. signal change after IOP administration

Conditions

Interventions

TypeNameDescription
DRUGIOP InjectionT1 and T2

Timeline

Start date
2018-04-01
Primary completion
2018-05-01
Completion
2018-07-31
First posted
2018-01-16
Last updated
2018-08-17

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT03399214. Inclusion in this directory is not an endorsement.